Gold prices bounce off 3-week lows; demand likely longer term
BELGRADE, Mont. - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a $95 million market cap company specializing in surgical solutions for spinal and orthopedic disorders, today announced the release of OsteoFactor Pro™, a new product aimed at enhancing bone healing. According to InvestingPro data, the company has demonstrated strong growth with revenue increasing 20.81% over the last twelve months. This growth factor-rich formula is engineered to support surgical procedures by improving the body’s natural bone regeneration processes.
OsteoFactor Pro™ is designed to work with orthobiologic scaffolds, providing an immediate release of growth factors followed by a sustained release to stimulate bone regeneration pathways such as angiogenesis, chemotaxis, and osteogenesis. The product can be used with synthetic, allograft, or autograft scaffolds and is now available through Xtant Medical’s distribution network.
Sean Browne, President and CEO of Xtant Medical, emphasized the company’s dedication to advancing healing science with biologics that are precise, flexible, and clinically impactful. COO Mark Schallenberger highlighted that with the introduction of OsteoFactor Pro™, Xtant is the first vertically integrated company to offer solutions across all five major orthobiologic categories. The company’s strategic expansion comes amid impressive market performance, with InvestingPro data showing a 70.5% price return over the past six months. Get access to 7 more exclusive ProTips and comprehensive analysis with an InvestingPro subscription.
Xtant Medical’s portfolio includes a range of orthobiologics and spinal implant systems designed to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company’s mission is centered on honoring organ donation to help patients lead fuller lives.
The press release also touches on non-GAAP financial measures used by the company, such as adjusted EBITDA, and includes forward-looking statements regarding revenue guidance and cash flow expectations for 2025. These statements are subject to risks and uncertainties, and actual results may differ materially. Based on current InvestingPro Fair Value analysis, XTNT appears to be trading near its Fair Value, with analysts setting price targets between $1.50 and $2.00 per share.
The information in this article is based on a press release statement from Xtant Medical Holdings, Inc.
In other recent news, Xtant Medical Holdings Inc reported a strong financial performance for the first quarter of 2025, with revenue reaching $32.9 million, an 18% increase from the previous year. The company achieved a net income of $58,000, marking a significant turnaround from the $4.4 million net loss in Q1 2024. This revenue exceeded forecasts by over $1.3 million, contributing to positive investor sentiment. Xtant Medical also announced the launch of two new products and expanded its processing capacity. Additionally, the company terminated a restrictive investor rights agreement and welcomed a new major investor. The firm’s strategic initiatives and market demand have been reflected in its improved financial metrics. Looking ahead, Xtant Medical has provided a revenue guidance range of $127 million to $131 million for the full year 2025, anticipating growth between 8% and 11%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.